Bristol Myers Squibb and Cellares Announce $380M Global Capacity Reservation and Supply Agreement for CAR-T Cell Therapy Manufacturing

Local timeOn April 22, Bristol Myers Squibb (BMS) and Cellares announced a global capacity reservation and supply agreement for the manufacturing of CAR-T cell therapies, with the deal valued at up to $380 million in upfront and milestone payments.

As part of the agreement, Cellares will optimize, automate BMS CAR-T cell therapy and transfer its technology to its automated and high-throughput manufacturing platform—the Cell Shuttle™. Cellares will be committed to providing multiple Cell Shuttles and Cell Q™ systems for BMS's exclusive use, featuring full automation and high-throughput quality control. The Cell Shuttles and Cell Qs will be deployed in Cellares' smart factories in the United States, the European Union, and Japan.

Hot Topic

Advances in the Clinical Development of NK Cell Therapy

Opportunities and Challenges in the Original Development of Cell Therapy Drugs

Development Strategies for iPSC-Derived NK Cell Therapy in Tumor Treatment

Exploration of Payment Methods for CAR-T Cell Therapy

Market Opportunities and Challenges for TIL Therapy

Research Progress of CAR-NK Cell Therapy in the Treatment of Hematological Tumors

Development Strategies for CAR-T Cell Therapy in Glioblastoma

Development and Challenges of CAR-T Cell Therapy Derived from Cord Blood

Clinical Exploration of CLDN18.2-Targeted CAR-T in Solid Tumors

Application of mRNA Technology in CAR Cell Therapy

Progress in TCR-T Cell Therapy for Solid Tumors

Development Strategies for CAR-M Cell Therapy

Roundtable: Feasibility Discussion on the Global Commercialization of Cell Drugs Entering a Boom Period

Roundtable: Technological Innovation Opportunities in Tumor Immunotherapy

Scan the code

Time-limited Collection

Free Tickets

Hotline for Cooperation

18701871600 (Manager Wang)

15572286596 (Manager Yuan)

15221150919 (and Manager)

Manufacturing cell therapies is complex both operationally and technically. As cell therapies are rapidly transforming the treatment of many different diseases, the demand for these treatments is significantly increasing. This collaboration enables Bristol-Myers Squibb to expand its manufacturing capabilities, meeting the growing needs of its diverse cell therapy portfolio through a scalable platform, with the potential to improve turnaround times and deliver the promise of faster cell therapies to more patients.

President of Bristol-Myers Squibb’s Cell Therapy Organization, Lynelle B. Hoch, said: "The agreement with Cellares represents the latest step in supporting our comprehensive strategy to unlock the full potential of CAR-T therapies and provide transformative treatments to as many patients as possible. Our collaboration with Cellares enhances our internal manufacturing capabilities for CAR-T cell therapy, giving us access to the first end-to-end automated cell therapy manufacturing platform, helping ensure we meet the high demand for these differentiated therapies, both now and in the future."

This agreement expands the existing collaboration between Bristol-Myers Squibb and Cellares. In August 2023, Bristol-Myers Squibb participated in Cellares' Series C funding round and launched the first Integrated Development and Manufacturing Organization (IDMO) smart factory, striving to meet the global demand for cell therapies. In the same month, Bristol-Myers Squibb joined Cellares’ Technology Adoption Partnership (TAP) program to evaluate the automated manufacturing capabilities of the Cell Shuttle.

Cellares CEO and Co-Founder Fabian Gerlinghaus stated, "This agreement with Bristol-Myers Squibb aligns with our strategy to build a global network of high-throughput, automated smart factories to meet the growing global demand for cell therapies. We look forward to demonstrating how our innovative technology’s focus on standardization can accelerate commercial-scale manufacturing and global deployment. Our collaboration with Bristol-Myers Squibb, along with our collective expertise, further advances our mission to...Accelerate Global Patients' Access to Life-Saving Cell Therapies。”

References:

1.https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-and-Cellares-Announce-a-380M-Worldwide-Capacity-Reservation-and-Supply-Agreement-for-the-Manufacture-of-CAR-T-Cell-Therapies-to-Bring-the-Promise-of-Cell-Therapy-to-More-Patients-Faster/default.aspx

Live Broadcast Preview

On April 25, Advances in the Application of Cutting-edge Cell Analysis Technology Accelerate Innovation in Drug and Immunotherapy Research

Dian Dian "Share”、“Like" and "In Progress", charge me up a bit~"